BIAF
bioAffinity Technologies, Inc.
There isn't enough reported data to score BIAF yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BIAF Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
BIAF's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BIAF PE Valuation
BIAF has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BIAF Forward outlook
There aren't enough analyst estimates for BIAF to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BIAF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$81.49 | +$228.11 |
| Q2 2026 | -$146.70 | +$163.80 |
| Q1 2026 | -$213.60 | +$105.90 |
| Q4 2025 | -$273.45 | +$64.05 |
| Q3 2025 | -$309.60 | +$59.40 |
| Q2 2025 | -$310.50 | +$103.50 |
| Q1 2025 | -$319.50 | +$99.00 |
| Q4 2024 | -$337.50 | +$72.00 |
BIAF has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BIAF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -26% |
| Q2 2026 | $1.5M | +19% |
| Q1 2026 | $1.4M | -27% |
| Q4 2025 | $1.6M | -28% |
| Q3 2025 | $1.4M | -38% |
| Q2 2025 | $1.3M | -47% |
| Q1 2025 | $1.9M | -23% |
| Q4 2024 | $2.2M | -71% |
BIAF's revenue has slid since its 2023 peak: $1M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -328% | -169 points |
| Q2 2026 | -221% | -23 points |
| Q1 2026 | -268% | -126 points |
| Q4 2025 | -197% | -64 points |
| Q3 2025 | -159% | -75 points |
| Q2 2025 | -198% | -111 points |
| Q1 2025 | -142% | -61 points |
| Q4 2024 | -133% | -103 points |
BIAF's operating margin was −328% last quarter, down 169 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BIAF on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over BIAF on profitability, with a higher operating margin.
BIAF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.9M | -$1.5M |
| Q2 2026 | -$3.3M | -$630.4K |
| Q1 2026 | -$3.2M | -$1.5M |
| Q4 2025 | -$2.6M | -$882.4K |
| Q3 2025 | -$2.5M | -$758K |
| Q2 2025 | -$2.7M | -$1.1M |
| Q1 2025 | -$1.7M | +$694.8K |
| Q4 2024 | -$1.7M | -$74.3K |
BIAF has burned cash in almost every quarter: −$13M over the past year, against −$9M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BIAF on cash generation, producing positive trailing cash flow while its opponent burns cash.
BIAF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +157% | +548K shares |
| 1 year | +1579% | +843K shares |
| 3 years | +9494% | +887K shares |
BIAF has 896,271 diluted shares, up 1579% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BIAF on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BIAF Net Leverage
BIAF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BIAF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 1.0 | Oversold |
BIAF's weekly RSI is 34 (neutral) and its Stochastic is 1 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BIAF PE vs Healthcare Sector
BIAF has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BIAF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.15 | 44% below |
| 20 week MA | $7.21 | 68% below |
| 50 week MA | $18.6 | 87% below |
| 100 week MA | $94.0 | 98% below |
| 200 week MA | $449.1 | 99% below |
BIAF is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BIAF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $3,172.5 | $832.5 | -74% |
| 2023 | $832.5 | $661.5 | -21% |
| 2024 | $661.5 | $400.4 | -39% |
| 2025 | $400.4 | $17.6 | -96% |
| 2026 YTD | $17.6 | $2.34 | -87% |
BIAF has finished every year since 2022 lower, and it's down 87% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over BIAF on returns for 2026, with the stronger performance.